Michael Flaherty
Interventional Cardiology · Louisville, KYNPI 1821210584
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,750 of the $41,744 with a category attached, or 83.2%. Abiomed accounts for 92.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $16,093 and has fallen 99.5% since, to $86 in 2025.
Across 151 payments — averaging $276.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$39K
- Abbott$880
- Boston Scientific$271
- AstraZeneca$249
- Biotronik Inc.$240
- Medtronic$217
- plus $1K from 15 others
Across 39 payments — averaging $1160.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$44K
- Abbott$1K
What the payments were for
- Speaking & faculty fees$34,75083%
- Travel & lodging$2,4986%
- Food & beverage$4,47711%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 34 | $38,655 |
| Abbott | 28 | $880 |
| Boston Scientific | 10 | $271 |
| AstraZeneca | 3 | $249 |
| Biotronik Inc. | 9 | $240 |
| Medtronic | 6 | $217 |
| Novartis | 10 | $189 |
| Terumo Medical Corporation | 2 | $187 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $149 |
| Johnson & Johnson | 7 | $115 |
| Boehringer Ingelheim | 1 | $95 |
| Amgen | 5 | $82 |
| E.r. Squibb & Sons, L.L.C. | 5 | $81 |
| Pfizer | 5 | $74 |
| Cardiovascular Systems Inc. | 5 | $65 |
| Philips North America LLC | 2 | $49 |
| Impulse Dynamics (USA) Inc. | 2 | $45 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Merck | 2 | $33 |
| Vital Connect, Inc | 1 | $18 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$38,247
- FARXIGA$237
- DRAGONFLY OPSTAR$148
- MetaCross$116
- LOTUS EDGE$103
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$100
How this compares
$41,744 in reported general payments places this provider in the 85th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 654 | $527,184 |
| EntrestoSacubitril/Valsartan | 123 | $125,095 |
| XareltoRivaroxaban | 141 | $120,307 |
| BrilintaTicagrelor | 67 | $45,435 |
| JardianceEmpagliflozin | 61 | $23,821 |
| XifaxanRifaximin | 11 | $17,332 |
| Repatha SureclickEvolocumab | 25 | $15,770 |
| FarxigaDapagliflozin Propanediol | 12 | $14,247 |
| VascepaIcosapent Ethyl | 20 | $12,531 |
| Ranolazine ErRanolazine | 64 | $11,033 |
| Metoprolol Succinate | 692 | $8,814 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $7,905 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 75 | $7,211 |
| Midodrine Hcl | 57 | $6,640 |
| Repatha SyringeEvolocumab | 12 | $6,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $74 | $527,184654 claims |
| NovartisEntresto | $189 | $125,095123 claims |
| Johnson & JohnsonXarelto | $115 | $120,307141 claims |
| AstraZenecaBrilinta, Farxiga | $249 | $59,68279 claims |
| Boehringer IngelheimJardiance | $95 | $23,82161 claims |
| MerckJanumet, Januvia | $33 | $11,37727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Louisville
- Daniel StewartLouisville$290K
- Daniel RothschildLouisville$154K
- Naresh SolankhiLouisville$132K
- Ravi SharmaLouisville$86K
- Christopher SemderLouisville$50K
- Sadip PantLouisville$43K
- Prafull RahejaLouisville$27K
- Faraaz RahmanLouisville$22K
- Hussayn AlrayesLouisville$21K
- Ivan PenaLouisville$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.